About Solute carrier family 35 member E3
Solute carrier family 35 member E3 (SLC35E3) is a protein
from Homo sapiens identified by UniProt accession
Q7Z769, 313 residues long.
MolForge cross-references it against 0 known binders and
18 disease associations.
Target properties
| Protein name | Solute carrier family 35 member E3 |
|---|
| UniProt accession | Q7Z769 |
|---|
| Gene | SLC35E3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 313 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (18)
Diseases linked to this target (Open Targets).
- body height · score 0.38
- neurodegenerative disease · score 0.34
- mean corpuscular volume · score 0.19
- mean reticulocyte volume · score 0.19
- erythrocyte count · score 0.18
- red blood cell density measurement · score 0.16
- mean corpuscular hemoglobin concentration · score 0.11
- mean corpuscular hemoglobin · score 0.10
- lymphocyte count · score 0.09
- leukocyte count · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q7Z769-F1 | alphafold | PREDICTED | 87.45 | — |
Amino-acid sequence (313 residues)
MALLVDRVRG HWRIAAGLLF NLLVSICIVF LNKWIYVYHG FPNMSLTLVH FVVTWLGLYI CQKLDIFAPK SLPPSRLLLL ALSFCGFVVF TNLSLQNNTI GTYQLAKAMT TPVIIAIQTF CYQKTFSTRI QLTLIPITLG VILNSYYDVK FNFLGMVFAA LGVLVTSLYQ VWVGAKQHEL QVNSMQLLYY QAPMSSAMLL VAVPFFEPVF GEGGIFGPWS VSALLMVLLS GVIAFMVNLS IYWIIGNTSP VTYNMFGHFK FCITLFGGYV LFKDPLSINQ ALGILCTLFG ILAYTHFKLS EQEGSRSKLA QRP
Explore Solute carrier family 35 member E3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets